Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

Exclusion Criteria

• •history of tendon damage/disorders due to quinolone therapy
• •uncorrected hypokalemia
• •history of myasthenia gravis
• •intubated at the time of consent OR subject is a candidate for enrollment into the open-label S. aureus arm and has been intubated greater than 12 hours prior to randomization
• •mild CABP with a PORT score of less than II
• •viral, fungal, mycobacterial, or atypical pneumonia as a primary diagnosis
• •pneumonia suspected to be secondary to aspiration
• •primary, solitary lung abscess
• •healthcare-associated pneumonia, hospital-acquired pneumonia, or ventilator-associated pneumonia
• •known bronchial obstruction or a history of postobstructive pneumonia.
• •primary lung cancer or another malignancy metastatic to the lungs
• •cystic fibrosis, known or suspected Pneumocystis jiroveci (carinii) pneumonia, or known or suspected active tuberculosis
• •infection that necessitates the use of a concomitant antibacterial agent in addition to study medication
• •systemic antibiotics within the last 96 hours before randomization, with exceptions
• •hospitalized for greater than 72 hours for any reason 30 days before randomization (excluding the 24 hour period before enrollment).
• •history of a serious hypersensitivity reaction to any quinolone including moxifloxacin.
• •female and pregnant, breastfeeding, or may be pregnant.
• •Other protocol-specific eligibility criteria may apply